Research programme: oligonucleotide therapies - Ionis Pharmaceuticals
Latest Information Update: 25 Aug 2023
At a glance
- Originator Ionis Pharmaceuticals
- Class Oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified